Shanghai Xuerong Biotechnology Co., Ltd. (SHE:300511)
China · Delayed Price · Currency is CNY 5.39
-0.20 (-3.58%)
Sep 11, 2026, 4:00 PM EDT
SHE:300511 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 3,454 | 3,999 | 1,731 | 2,668 | 3,245 | 3,350 | |
Market Cap Growth | -0.69% | 131.03% | -35.13% | -17.76% | -3.14% | -41.93% |
Enterprise Value | 4,472 | 5,148 | 3,771 | 4,380 | 4,520 | 5,066 |
Last Close Price | 5.39 | 6.24 | 3.47 | 5.35 | 6.45 | 7.58 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 22.38 | 134.22 | - | - | - | - |
Forward PE | - | 8.61 | 8.61 | 13.05 | 7.90 | 8.42 |
PS Ratio | 1.47 | 2.01 | 0.80 | 1.04 | 1.40 | 1.62 |
PB Ratio | 2.25 | 2.64 | 2.10 | 1.86 | 2.00 | 2.03 |
P/TBV Ratio | 2.57 | 3.05 | 2.71 | 2.14 | 2.13 | 2.50 |
P/FCF Ratio | 11.30 | 11.89 | 15.77 | - | 68.08 | - |
P/OCF Ratio | 6.93 | 9.62 | 3.96 | 7.46 | 8.84 | 13.73 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 1.90 | 2.59 | 1.74 | 1.71 | 1.95 | 2.44 |
EV/EBITDA Ratio | 8.71 | 12.61 | 18.07 | 21.17 | 11.49 | 28.43 |
EV/EBIT Ratio | 24.53 | 71.94 | - | - | 84.51 | - |
EV/FCF Ratio | 14.63 | 15.31 | 34.36 | - | 94.83 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.85 | 0.85 | 2.61 | 1.52 | 1.07 | 1.21 |
Debt / EBITDA Ratio | 2.53 | 3.15 | 10.11 | 10.36 | 4.42 | 11.13 |
Debt / FCF Ratio | 4.24 | 3.84 | 19.57 | - | 36.60 | - |
Net Debt / Equity Ratio | 0.73 | 0.75 | 2.40 | 1.35 | 0.68 | 1.01 |
Net Debt / EBITDA Ratio | 2.19 | 2.77 | 9.49 | 9.32 | 2.82 | 9.34 |
Net Debt / FCF Ratio | 3.67 | 3.36 | 18.04 | -2.61 | 23.30 | -4.23 |
Asset Turnover | 0.66 | 0.53 | 0.51 | 0.59 | 0.55 | 0.47 |
Inventory Turnover | 5.68 | 4.97 | 5.54 | 5.44 | 5.08 | 5.28 |
Quick Ratio | 0.14 | 0.12 | 0.11 | 0.14 | 0.55 | 0.24 |
Current Ratio | 0.37 | 0.35 | 0.28 | 0.36 | 0.92 | 0.55 |
Return on Equity (ROE) | 11.04% | 3.29% | -54.65% | -12.58% | -24.05% | -19.11% |
Return on Assets (ROA) | 3.19% | 1.20% | -2.39% | -1.65% | 0.80% | -1.88% |
Return on Invested Capital (ROIC) | 7.01% | 2.58% | -5.24% | -3.75% | 1.77% | -4.13% |
Return on Capital Employed (ROCE) | 9.60% | 3.90% | -8.50% | -4.60% | 1.90% | -4.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 4.35% | 0.74% | -35.65% | -7.05% | -8.85% | -9.30% |
FCF Yield | 8.85% | 8.41% | 6.34% | -27.70% | 1.47% | -11.74% |
Payout Ratio | 17.74% | 143.25% | - | - | - | - |
Buyback Yield / Dilution | -19.94% | -19.74% | -0.55% | -1.66% | -12.49% | 0.46% |
Total Shareholder Return | -19.94% | -19.74% | -0.55% | -1.66% | -12.49% | 0.46% |